Get the Stockscreener App
0.7449
2.27%
0.0165
After Hours:
.75
0.0051
+0.68%
Tenaya Therapeutics Inc stock is traded at $0.7449, with a volume of 2.65M.
It is up +2.27% in the last 24 hours and down -47.17% over the past month.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
See More
Previous Close:
$0.7284
Open:
$0.75
24h Volume:
2.65M
Relative Volume:
0.54
Market Cap:
$161.28M
Revenue:
-
Net Income/Loss:
$-111.13M
P/E Ratio:
-0.5643
EPS:
-1.32
Net Cash Flow:
$-91.53M
1W Performance:
+6.41%
1M Performance:
-47.17%
6M Performance:
+21.74%
1Y Performance:
-50.99%
1-Day Range:
$0.7181
$0.7625
1-Week Range:
$0.68
$0.7627
52-Week Range:
$0.36
$2.35
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
Name
Tenaya Therapeutics Inc
Sector
Industry
Phone
415-865-2066
Address
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Compare TNYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
0.7449 | 157.70M | 0 | -111.13M | -91.53M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-24 | Initiated | William Blair | Outperform |
| Nov-30-23 | Initiated | Leerink Partners | Outperform |
| Jun-15-22 | Initiated | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc Stock (TNYA) Latest News
Tenaya Therapeutics Inc. (TNYA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Tenaya Therapeutics announces orderly board leadership transition - TipRanks
Buy Signal: Is Tenaya Therapeutics Inc stock supported by strong fundamentalsPortfolio Update Report & Daily Volume Surge Signals - moha.gov.vn
How Tenaya Therapeutics Inc. stock reacts to Fed rate cutsLow Beta Stocks & Budget Friendly Investment Plans - bollywoodhelpline.com
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Tenaya Therapeutics price target lowered to $4 from $6 at Canaccord - MSN
Why Tenaya Therapeutics Inc. stock is rated strong buy2025 Price Momentum & Free Expert Verified Stock Movement Alerts - Bölüm Sonu Canavarı
Buyout Rumor: Why Tenaya Therapeutics Inc stock is recommended by analystsMarket Activity Report & Reliable Trade Execution Plans - moha.gov.vn
Is International Seaways Inc stock attractive for ETFsMarket Risk Analysis & Smart Money Movement Tracker - moha.gov.vn
Leerink Partners Reaffirms Their Buy Rating on Tenaya Therapeutics (TNYA) - The Globe and Mail
Will Tenaya Therapeutics Inc. stock outperform growth indexesWeekly Market Outlook & Long Hold Capital Preservation Plans - Улправда
Is Tenaya Therapeutics Inc. stock positioned for long term growth2025 Performance Recap & Low Drawdown Momentum Ideas - Улправда
Will Tenaya Therapeutics Inc. stock remain a Wall Street favorite2025 Top Gainers & Consistent Profit Trading Strategies - DonanımHaber
Will Tenaya Therapeutics Inc. stock deliver shareholder valueQuarterly Investment Review & Expert-Curated Trade Recommendations - DonanımHaber
Canaccord Genuity Keeps Their Buy Rating on Tenaya Therapeutics (TNYA) - The Globe and Mail
Sell Signal: What catalysts could drive Tenaya Therapeutics Inc. stock higher2025 Key Lessons & Proven Capital Preservation Tips - Улправда
Tenaya Therapeutics stock price target lowered to $5 at Canaccord By Investing.com - Investing.com Canada
FY2025 Earnings Forecast for TNYA Issued By Lifesci Capital - MarketBeat
Tenaya Therapeutics stock price target lowered to $5 at Canaccord - Investing.com India
Wilson Sonsini Advises Tenaya Therapeutics on Pricing of Public Offering - Wilson Sonsini
H.C. Wainwright lowers Tenaya Therapeutics stock price target to $3 on ARVC trial data By Investing.com - Investing.com Australia
Tenaya fundraising follows resolution of clinical hold - The Pharma Letter
H.C. Wainwright lowers Tenaya Therapeutics stock price target to $3 on ARVC trial data - Investing.com Nigeria
Tenaya Therapeutics announces proposed public offering - MSN
Tenaya Therapeutics price target lowered to $3 from $5 at HC Wainwright - MSN
Tenaya Therapeutics (TNYA) Is Down 39.7% After Cardiac Gene Therapy Milestones And $60M FundraiseWhat's Changed - Yahoo Finance
Tenaya Therapeutics announces clinical hold on MyPEAK-1 trial lifted by FDA - MSN
Tenaya Therapeutics (NASDAQ:TNYA) Given New $3.00 Price Target at HC Wainwright - MarketBeat
Chardan Capital Lowers Tenaya Therapeutics (NASDAQ:TNYA) Price Target to $8.00 - MarketBeat
Tenaya Therapeutics Announces Public Offering Pricing - The Globe and Mail
Chardan Capital Maintains Tenaya Therapeutics (TNYA) Buy Recommendation - Nasdaq
HC Wainwright & Co. Maintains Tenaya Therapeutics (TNYA) Buy Recommendation - Nasdaq
Tenaya Therapeutics (NASDAQ: TNYA) details $60 million unit and warrant sale - Stock Titan
Pharma News: Will Tenaya Therapeutics Inc stock remain a Wall Street favorite2025 Market Sentiment & Weekly Return Optimization Plans - moha.gov.vn
Tenaya Stock Plunges After $60 Million Equity Offering - Sahm
Tenaya Stock Drops After Announcing $60M Equity OfferingTenaya Therapeutics (NASDAQ:TNYA) - Benzinga
Tenaya Therapeutics (TNYA) Price Target Lowered by HC Wainwright & Co. | TNYA Stock News - GuruFocus
Tenaya Therapeutics slumps after $60 million share sale - TradingView — Track All Markets
Tenaya Therapeutics plans to offer stock and warrant units By Investing.com - Investing.com India
Tenaya Therapeutics Prices 50 Mln Unit Offering At $60 Mln, Clinical Hold Lifted On TN-201 - Nasdaq
Tenaya Therapeutics announces positive data from Phase 1b/2 trial - Traders Union
TNYA: Chardan Capital Lowers Price Target While Maintaining Buy Rating | TNYA Stock News - GuruFocus
FDA lifts clinical hold on Tenaya’s heart disease gene therapy trial - Investing.com Australia
Tenaya Therapeutics Prices $60 Million Unit Offering - marketscreener.com
Tenaya Therapeutics prices $60 million public offering of stock and warrants - Investing.com Nigeria
Tenaya Therapeutics Announces Pricing of Public Offering - The Manila Times
Tenaya Therapeutics prices $60 million public offering of stock and warrants By Investing.com - Investing.com South Africa
Tenaya Therapeutics Announces Pricing of Public Offering | Associated Press | syndication news - Enidnews.com
Tenaya Therapeutics presents new interim safety, efficacy data on TN-201 - MSN
Tenaya Therapeutics stock falls on proposed share and warrant offering By Investing.com - Investing.com Canada
Tenaya Therapeutics, Inc. (TNYA) Discusses Initial Data From RIDGE-1 Phase Ib/II Trial of TN-401 Gene Therapy for ARVCSlideshow (NASDAQ:TNYA) 2025-12-11 - Seeking Alpha
Tenaya Therapeutics Inc Stock (TNYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tenaya Therapeutics Inc Stock (TNYA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tingley Whittemore | Chief Medical Officer |
Nov 17 '25 |
Sale |
1.33 |
2,877 |
3,826 |
169,926 |
| Ali Faraz | Chief Executive Officer |
Nov 17 '25 |
Sale |
1.33 |
3,126 |
4,158 |
299,666 |
| Higa Tomohiro | SVP, Finance |
Aug 18 '25 |
Sale |
1.25 |
2,962 |
3,711 |
95,338 |
| Tingley Whittemore | Chief Medical Officer |
Aug 18 '25 |
Sale |
1.25 |
5,053 |
6,331 |
172,803 |
| Ali Faraz | Chief Executive Officer |
Aug 18 '25 |
Sale |
1.25 |
14,533 |
18,210 |
302,792 |
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):